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The maximal activities of the key glycolytic enzymes hexokinase and 6-phosphofructokinase, were reduced 
in brown adipose tissue in db/db mice compared to their lean littermates. Treatment of db/db mice with 
the thermogenic B_adrenoceptor agonist, BRL 26830, restored normoglycaemia. The only signifwnt in- 
crease in activity of hexokinase and ~~os~hof~ctokina~ in the BRL 2683~treated b/db mice occurred 
in brown adipose tissue where the total tissue activity increased lo- and 1 l-fold respectively. These changes 
together with increased 2deoxyglucose uptake in vivo suggest hat brown adipose tissue can piay a quanti- 
tatively important role in the removal of glucose from the blood. 
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1. INTRODUCTION 
The role of brown adipose tissue as a major site 
of non-shivering thermogenesis n hibernators and 
other small mammals and in the newborn of larger 
mammals is now well established [1,2]. It is 
generally accepted that fatty acids are the oxidative 
fuel for non-shivering thermogenesis [1,3] but 
there is no direct evidence that this is always the 
case [4]. In animals fed on a high carbohydrate 
diet, blood glucose might be a direct substrate for 
thermogenesis n brown adipose tissue as well as an 
indirect substrate via its role as a lipogenic precur- 
sor [S,6]. If this is so, brown adipose tissue may 
play an important quantitative role in the regula- 
tion of blood glucose [7]. In support of this argu- 
ment, it has been shown that the glycolytic capaci- 
ty of brown adipose tissue as indicated by the max- 
imum activity of glucose phosphorylation (hex- 
okinase) is appro~mately 25% of that of the liver 
in normal rats and equal to the liver in cold- 
acclimated rats [7]. 
CS7BIIKsJ db/db mice are both obese and 
diabetic [8]. The development of obesity, which 
precedes the development of overt diabetes, is at- 
tributed to a defective activation of non-shivering 
thermogenesis 191. The reasons for the develop- 
ment of diabetes are less well understood and 
defects in both insulin secretion [lo] and insulin ac- 
tion [11] have been demonstrated. Notwithstand- 
ing the primary cause of the diabetic condition, if 
brown adipose tissue is normally a major site of 
glucose utilisation in small mammals, then defec- 
tive activation of thermogenesis in dbldb mice 
could contribute to the glucose intolerance of these 
mice. 
Here, the maximum activities of hexokinase, 
6-phosphofructokinase and 2-oxoglutarate dehy- 
drogenase have been measured in selected tissues 
of db/db mice and their lean littermates. These en- 
zymes provide a quantitative index of the max- 
imum capacity of glycolysis from glucose, glycoiy- 
sis from glycogen, and the tricarboxylic acid cycle 
activity [7,12] respectively. In addition, measure- 
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ments have been made of the relative tissue uptake 
of 2-deoxyglucose in vivo. Finally, the effect of 
chronic administration of a thermogenic ,&adreno- 
ceptor agonist on these parameters was deter- 
mined. 
2. MATERIALS AND METHODS 
Female C57Bl/KsJ db/db mice and their lean lit- 
termates were obtained from Jackson Laborator- 
ies, Bar Harbour, ME. The mice used came from 
a stock in which the db gene was in opposition to 
the coat colour gene misty. The lean littermates 
were all db+/+m, the mice were aged 4/S weeks 
upon purchase and were maintained at 23 ~fi: 1°C 
under a 12 h light-12 h dark light cycle. During 
this time, they were fed on Oxoid rat and mouse 
breeders diet (H.C. Styles, Bewdley, Worcs.). 
Chemicals and enzymes were obtained from 
Boehringer (Lewes, Sussex) or Sigma (Poole, 
Dorset). _ 
In experiments to study the effect of chronic 
treatment with a thermogenic p-agonist, BRL 
26830 [ 131, (R*,R*)-( f )-methyl 4-[2-[(2-hydroxy- 
2-phenylethyl)amino]propyl]benzoate, (B-2- 
butenedioate (2: 1) salt, was given as dietary ad- 
mixture (5 mg/lOO g diet) for 10 weeks (enzyme 
studies) or 8 days (2deoxyglucose studies). To 
measure enzyme activity, tissues were removed 
from the mice and homogenized in 11 volumes of 
an extraction medium containing (mM) 50 Tris, 1 
EDTA, 5 MgClz and 0.02 ,&mercaptoethanol, at 
pH 8.2. For the measurement of 2-oxoglutarate 
dehydrogenase, dithiothreitol (1 mM) replaced 
mercaptoethanol. Hexokinase, 6_phosphofructo- 
kinase and 2-oxoglutarate dehydrogenase were 
measured spectrophotometrically [14- 161. Since 
liver possesses both hexokinase and glucokinase 
activities [ 171, total glucose phosphorylating activi- 
ty was determined in the presence of 100 mM 
glucose. This is not necessary for brown adipose 
tissue since phosphorylation of glucose is catalyzed 
by hexokinase [7]. 
Mitochondrial proteins were separated by 
discontinuous slab gel electrophoresis and the 
relative amount of uncoupling protein (Mr 32000) 
was determined as described previously [ 181. Brief- 
ly, proteins were located using protein markers (MI 
14000-62000). Only the 32000-Da protein showed 
changes in height relative to other mitochondrial 
protein bands and its height was therefore 
measured relative to an adjacent band (MI 30000). 
To determine relative tissue uptake of 
2-deoxyglucose in vivo, conscious mice were given 
2-deoxy-[‘4C]glucose (0.2 &i/mouse) in 0.2 ml 
saline by intravenous injection. After 45 min, the 
mice were killed and blood was obtained for the 
measurement of glucose and radiochemical con- 
tent. The mice were rapidly dissected and samples 
taken for combustion in a tissue oxidiser. The 
results are expressed as r4C dpm in tissue/14C dpm 
in whole animal. 
3. RESULTS AND DISCUSSION 
The maximum activities of hexokinase, 6-phos- 
phofructokinase and 2-oxoglutarate dehydrogen- 
ase in various tissues of C57Bl/KsJ db/db mice 
and their lean litterrnates are given in table 1. The 
activities of 6-phosphofructokinase and 2-oxoglu- 
tarate dehydrogenase were increased 5- and 3-fold, 
respectively, in the livers of the db/db mice. Liver 
enzyme changes are well documented for obese- 
diabetic animals and are thought to be associated 
with but not causal of the obesity [19]. The 
activities of all three enzymes were decreased in the 
quadriceps muscle of the db/db mice. This was in 
part due to a decrease in muscle mass. 
In brown adipose tissue of db/db mice, the max- 
imum activities of all three enzymes on a whole 
tissue basis were significantly reduced relative to 
the lean littermates (table 1). If the enzyme ac- 
tivities are‘ expressed on a g wet weight of tissue 
basis, the’ reductions in,enzyme activities in brown 
adipose tissue we* further exaggerated (table 2). 
The maximum catalytic activity of hexokinase in 
muscle provides a quantitative index of the max- 
imal rate of glycolysis from glucose [ZO]. Table 1 
shows that the maximum activity of hexokinase in 
the interscapular brown adipose tissue of the lean 
littermates is 50% of the maximum activity of 
glucose phosphorylation (hexokinase and gluco- 
kinase) in liver. However, it is estimated that in- 
terscapular brown adipose tissue represents only 
25% of the total tissue in the mouse [21] and thus 
the glycolytic capacity of brown adipose tissue in 
these lean littermates exceeds that of liver and is 3 
times greater than the heart. It is therefore pro- 
bable that the tissue is of quantitative importance 
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Table 1 
Maximal activities of ph~phof~~okin~e, hexokinase and oxoghttarate 
dehydrogenase in various tissues of Idweek-old db/db and db/+ mice 
@mol/min per tissue) 
Phospho- Hexokinase + Oxoglutarate 
fructokinase glucokinase dehydrogenase 
Brown adipose 
tissue dbl + 4.1 f 0.7 0.92 f 0.07 1.66 f 0.14 
(interscapular) db/db 2.2 i 0.1* 0.60 f O.lO* 0.63 f 0.02*+* 
Liver db/ + 7.5 i 1.8 1.94 C!Z 0.36 2.34 f 0.22 
db/db 37.9 f 1.5**+ 1.51 * 0.23 6.52 f 0.25++’ 
Heart db/ + 5.5 f 0.9 0.43 f 0.08 0.92 f 0.04 
db/db 4.7 i 0.2 0.56 f 0.06 0.75 i 0.08 
Muscle db/c 28.0 f 3.2 0.07 f 0.02 0.20 f 0.04 
(quadriceps) db/db 6.8 f 0.5*** not detected 0.05 f O.Ol** 
Enzyme activities are presented as the mean f SE for 5 different mice and 
statistical significance (Student’s r-test) is indicated by * P c 0.05, ** P < 0.01, 
*** P < 0.001 
Table 2 
Effect of BRL 26830 on the maximum catalytic activities of hexokinase, phosphofructokinase 
and oxoglutarate dehydrogenase in interscapular brown adipose tissue of db/db mice 
db/ + db/db db/db + 
BRL 26830 
Interscapular b own 
adipose tissue wt (mg) 84.8 f 6.0 295.0 f 9.5 734.0 * 34.0 
Hexokinase 
(rtmol/min per g tissue) 10.4 f o-5*** 2.0 f 0.7 7.5 f 0.2+** 
Phosphofructokmase 
~mol/mm per g tissue) 34 * 9 + -. 2 9*** 8.1 f 2.4 29.1 f 0.4@‘“* 
Oxoglutarate dehydrogenase 
(umol/min per g tissue) 16.7 f 1.4*** 1.40 f 0.02 4.68 f 0.80** 
Total interscapular BAT 
~t~ond~~ protein (mg) 2.56 f 0.21* 1.86 f 0.25 8.25 f 0.83*** 
Ratio of protein bands 
(32 kDa/30 kDa) 0.51 f 0.01*** 0.23 f 0.03 0.57 f o&Y** 
The mice were treated with BRL 26830 for lo-11 weeks as described in section 2. Results are 
presented as mean f SE for 5 different mice and statistical significance (Student’s t-test) relative 
to untreated db/db mice is indicated by * P < 0.05, ** P c 0.01, *** P < 0.001 
in whole animal glucose unction and may play a 
role in the regulation of blood glucose. If this is the 
case, any reduction in the maximum glycolytic 
capacity, as seen in the db/db mice, could con- 
tribute to the development of diabetes. 
Previously, the thertiogenic ,&adreuoceptor 
agonist, BRL 26830, has been shown to have anti- 
obesity activity in a number of animal models [ 131 
and produck hypertrophy of brown adipose tissue 
1221. In addition, it produces an improvement in 
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glucose tolerance in obese animals [23]. In the cur- 
rent studies, when given to C57BVKsJ db/db mice 
as a dietary admixture, BRL 26830 produced a 
reduction in the blood glucose concentration from 
30.6 + 1.1 to 11.5 f 1.1 mM and virtually 
eliminated glycosuria. This was accompanied by a 
significant increase in the concentration of plasma 
insulin from 116 f 15 rU/ml to 279 f 57 pU/ml 
(mean f SE on lo-14 animals). Treatment of 
db/db mice with BRL 26830 led to a significant in- 
crease in the maximal activities of both glycolytic 
and tricarboxylate cyclic enzyme activities in 
brown adipose tissue (table 2). This effect of 
BRL 26830 was not seen in the lean littermates 
(not shown). Indeed, since there was also brown 
adipose tissue hypertrophy including increased 
mitochondrial protein and increased proportion of 
the 32-kDa protein, the maximum activities of hex- 
okinase, 6-phosphofructokinase and 2_oxoglutar- 
ate dehydrogenase in total interscapular brown 
adipose tissue of BRL 26830-treated b/db mice 
were increased 5-, 5- and 2-fold respectively 
relative to the lean littermates and lO-, ll- and 
6-fold relative to the untreated db/db mice. 
BRL 26830 did not significantly affect the max- 
imum activities of these enzymes in liver, heart or 
quadriceps muscle in either the db/db mice or their 
lean littermates. 
It is not possible to equate directly increases in 
the maximum capacity of the glycolytic pathway 
with increases in the actual flux through that 
pathway. Therefore, to provide some indication of 
relative glucose flux into various tissues, the up- 
take of 2-deoxy[r4C]glucose in vivo has been 
measured (table 3). This glucose analogue is 
transported across membranes by the same carrier 
as glucose, is phosphorylated by hexokinase but is 
not metabolized further 1241. Net uptake of 
2-deoxyglucose therefore reflects glucose con- 
sumed by a tissue. Two tissues which prove the ex- 
ception to this are the liver and kidney, which have 
significant glucose 6-phosphatase activity [25]. In 
these tissues trapped 2-deoxyglucose (i-phosphate 
can be dephosphorylated and returned to the 
blood. Preliminary experiments carried out in 
these laboratories showed that whole animal 
recovery of radio label in normoglycaemic lean 
mice was constant. However, with an increasing, 
circulating blood glucose concentration, there was 
a progressive, but linear (r = -0.83) decrease in 
the overall recovery. This related to an increase in 
the urinary losses of 2-deoxy[‘4C]glucose. 
Since treatment of the db/db mice with 
BRL 26830 led to a substantial fall in the blood 
glucose concentration within 3 days of treatment, 
Table 3 
Effect of BRL 26830 on the relative tissue uptake of 2-deoxyglucose 
glucose uptake in vivo in db/db mice 
2-Deoxyglucose uptake 
(qo whole animal) 
db/db db/db + 
BRL 26830 
Interscapular brown 
adipose tissue 0.40 f 0.05 1.85 f 0.27+** 
Liver 11.53 f 0.89 9.03 f 0.56 
Heart 1.38 f 0.23 4.10 f 0.39+** 
Brain 1.56 f 0.40 1.01 f 0.09 
Kidneys 5.26 f 0.55 2.46 f 0.29*+* 
Quadriceps 0.46 f 0.06 0.57 f 0.07 
White adipose tissue (per g) 0.71 f 0.08 0.56 f 0.04 
db/db mice were treated with BRL 26830 for 8 days. As a result, blood 
glucose concentration fell from 30.6 it 1.1 to 11.6 f 1 .l mM. Results are 
expressed as r4C in total tissue (except white adipose tissue)/14C 
recovered in animal (see text). Each value is the mean f SE of 9 mice. 
+** P < 0.001 
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2-deoxyglucose uptake was measured after a 
shorter period (8 days) than those of enzyme 
measurements. The 2-deoxyglucose was intro- 
duced into different sized glucose pools in the two 
sets of mice. Thus, it is not possible to make direct 
comparisons between the two groups of mice with 
respect to 2-deoxyglucose uptake into individual 
tissues. However, it is possible to make com- 
parisons between different tissues within each 
group of mice. In the control db/db mice, uptake 
of 2-deoxyglucose into total brown adipose tissue 
was similar to that of the brain and heart (assum- 
ing that interscapular brown adipose tissue com- 
prises 25% of the total tissue). Following treat- 
ment of the db/db mice with BRL 26&30, there 
was a selective increase in the uptake of 2-deoxy- 
glucose by brown adipose tissue so that the inter- 
scapular brown adipose tissue alone now con- 
sumed more 2-deoxyglucose than brain. These 
findings, taken together with the measurement of 
maximum enqme activities of hexokinase and 
6-phosphofructokinase, suggest that brown 
adipose tissue in the diabetic mouse has a low 
capacity for glucose utilisation and this plays an 
important role in the development of diabetes in 
this animal. 
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